BACKGROUND: Chronic inflammation has been linked with geriatric-related conditions, including dementia. Inflammatory cytokine levels, including interleukin (IL)-6, IL-10, and tumor necrosis factor (TNF) α, in the blood have been associated with cognitive impairment and decline. However, evidence has been mixed. METHODS: We examined the cross-sectional and longitudinal associations between baseline-measured IL-6, IL-10, and TNFα levels and the ratio of IL-6/IL-10 with cognitive test performance and mild cognitive impairment (MCI) among 1,602 community-dwelling older adults (median age = 72.8) enrolled in the Mayo Clinic Study of Aging. Approximately half (46.5%) of participants were female and 98.6% were white. At baseline and follow-up visits (occurring at 15-month intervals), participants completed neuropsychological testing, blood draws, and had a clinical consensus diagnosis. RESULTS: In multivariable cross-sectional analyses, we did not observe an association between inflammatory cytokine levels and global or domain-specific cognitive z scores; however, higher IL-6 and IL-10 levels were associated with greater odds of a MCI diagnosis. Longitudinally, we did not observe any association between inflammatory cytokine levels and cognitive test performance or risk of MCI. Sex, age, cognitive status, APOE ε4 genotype, diabetes, depression, and cerebral amyloid-beta deposition were not effect modifiers. CONCLUSIONS: These results suggest that plasma inflammatory markers may not be useful to ascertain risk for cognitive decline and MCI in the general population.
BACKGROUND: Chronic inflammation has been linked with geriatric-related conditions, including dementia. Inflammatory cytokine levels, including interleukin (IL)-6, IL-10, and tumor necrosis factor (TNF) α, in the blood have been associated with cognitive impairment and decline. However, evidence has been mixed. METHODS: We examined the cross-sectional and longitudinal associations between baseline-measured IL-6, IL-10, and TNFα levels and the ratio of IL-6/IL-10 with cognitive test performance and mild cognitive impairment (MCI) among 1,602 community-dwelling older adults (median age = 72.8) enrolled in the Mayo Clinic Study of Aging. Approximately half (46.5%) of participants were female and 98.6% were white. At baseline and follow-up visits (occurring at 15-month intervals), participants completed neuropsychological testing, blood draws, and had a clinical consensus diagnosis. RESULTS: In multivariable cross-sectional analyses, we did not observe an association between inflammatory cytokine levels and global or domain-specific cognitive z scores; however, higher IL-6 and IL-10 levels were associated with greater odds of a MCI diagnosis. Longitudinally, we did not observe any association between inflammatory cytokine levels and cognitive test performance or risk of MCI. Sex, age, cognitive status, APOE ε4 genotype, diabetes, depression, and cerebral amyloid-beta deposition were not effect modifiers. CONCLUSIONS: These results suggest that plasma inflammatory markers may not be useful to ascertain risk for cognitive decline and MCI in the general population.
Authors: Andrew P Keegan; Daniel Paris; Cheryl A Luis; Laila Abdullah; Ghania Ait-Ghezala; David Beaulieu-Abdelahad; Makenzie Pryor; Jillian Chaykin; Gogce Crynen; Fiona Crawford; Michael Mullan Journal: Int J Geriatr Psychiatry Date: 2017-06-22 Impact factor: 3.485
Authors: Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Joshua J Pankratz; Scott M Brue; Walter A Rocca Journal: Int J Epidemiol Date: 2012-11-18 Impact factor: 7.196
Authors: Clifford R Jack; Heather J Wiste; Timothy G Lesnick; Stephen D Weigand; David S Knopman; Prashanthi Vemuri; Vernon S Pankratz; Matthew L Senjem; Jeffrey L Gunter; Michelle M Mielke; Val J Lowe; Bradley F Boeve; Ronald C Petersen Journal: Neurology Date: 2013-02-27 Impact factor: 9.910
Authors: Johan Sundelöf; Lena Kilander; Johanna Helmersson; Anders Larsson; Elina Rönnemaa; Malin Degerman-Gunnarsson; Hans Basun; Lars Lannfelt; Samar Basu Journal: J Alzheimers Dis Date: 2009 Impact factor: 4.472
Authors: Keenan A Walker; Ron C Hoogeveen; Aaron R Folsom; Christie M Ballantyne; David S Knopman; B Gwen Windham; Clifford R Jack; Rebecca F Gottesman Journal: Neurology Date: 2017-11-01 Impact factor: 9.910
Authors: Anna Morozova; Yana Zorkina; Olga Abramova; Olga Pavlova; Konstantin Pavlov; Kristina Soloveva; Maria Volkova; Polina Alekseeva; Alisa Andryshchenko; Georgiy Kostyuk; Olga Gurina; Vladimir Chekhonin Journal: Int J Mol Sci Date: 2022-01-22 Impact factor: 5.923
Authors: Jennifer St Sauver; Walter Rocca; Nathan LeBrasseur; Alanna Chamberlain; Janet Olson; Debra Jacobson; Michaela McGree; Michelle Mielke Journal: J Int Med Res Date: 2022-07 Impact factor: 1.573
Authors: Cutter A Lindbergh; Kaitlin B Casaletto; Adam M Staffaroni; Fanny Elahi; Samantha M Walters; Michelle You; John Neuhaus; Will Rivera Contreras; Paul Wang; Anna Karydas; Jesse Brown; Amy Wolf; Howie Rosen; Yann Cobigo; Joel H Kramer Journal: J Gerontol A Biol Sci Med Sci Date: 2020-07-13 Impact factor: 6.053
Authors: Sagar B Dugani; Luke R Christenson; Jeremiah A Aakre; Hai H Bui; Adrian Vella; Michelle M Mielke Journal: Diabetes Res Clin Pract Date: 2021-07-29 Impact factor: 8.180
Authors: Anna Kurowska; Iwona Bodys-Cupak; Magdalena Staszkiewicz; Joanna Szklarczyk; Joanna Zalewska-Puchała; Anna Kliś-Kalinowska; Marta Makara-Studzińska; Anna Majda Journal: Int J Environ Res Public Health Date: 2020-05-21 Impact factor: 3.390
Authors: Diego Z Carvalho; Erik K St Louis; Scott A Przybelski; Timothy I Morgenthaler; Mary M Machulda; Bradley F Boeve; Ronald C Petersen; Clifford R Jack; Jonathan Graff-Radford; Prashanthi Vemuri; Michelle M Mielke Journal: Front Aging Neurosci Date: 2022-07-11 Impact factor: 5.702